Zydus Lifesciences announced that it has obtained approval from the USFDA to sell a generic medication for the treatment of postherpetic neuralgia. The company has received the final nod from the US Food and Drug Administration (USFDA) to produce and distribute Gabapentin tablets in strengths of 300 mg and 600 mg, as stated in a regulatory filing by Zydus Lifesciences.
